Editas Medicine Garners $120,000,000 New Funding

  • Feed Type
  • Date
  • Company Name
    Editas Medicine
  • Mailing Address
    300 Third Street 1st Floor Cambridge, MA 02142 USA
  • Company Description
    The company’s mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    With this financing, we have a strong foundation from which we can broadly develop our genome editing platform and advance multiple new therapies toward clinical trials.
  • M&A Terms
  • Venture Investor
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    Viking Global Investors
  • Venture Investor
    Fidelity Management & Research Company
  • Venture Investor
    T. Rowe Price
  • Venture Investor
    Google Ventures
  • Venture Investor
    Jennison Associates
  • Venture Investor
    Khosla Ventures
  • Venture Investor
    EcoR1 Capital Management
  • Venture Investor
    Casdin Capital
  • Venture Investor
    Omega Funds
  • Venture Investor
    Cowen Capital Partners
  • Venture Investor
    Alexandria Venture Investments
  • Venture Investor
    Bill & Melinda Gates Foundation

Trending on Xconomy